metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction

DBCOND0144316Malignant and unspecified neoplasms gastrointestinal NEC Malignant Neoplasms

metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction is the indication for 2 drugs in DrugBank. It is covered by 6 curated, structured indications.

Classified under: Malignant and unspecified neoplasms gastrointestinal NEC
Malignant Neoplasms
Indicated drugs: Pembrolizumab
Trastuzumab deruxtecan

What you can answer from here — as of October 22, 2026

2Indicated drugsWith each drug's targets and mechanism

Listed above

6Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

Which approved drugs for metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account